| Vaccine efficacya | Method | Source | |||
---|---|---|---|---|---|---|
RV1 | Mild (RV episode without medical care) | Moderate (GP visit) | Severe (Hospitalization)b | Nosocomialc | Â | Â |
After first dose | Calculated | Calculated | 89.8% (8.9 to 99.8) | Calculated | (Calculated from) Published data Efficacy for mild and moderate cases after first season calculated from efficacy ratios for mild, moderate, severe during first season | [53] |
First season (after second dose) | 71.7% (50.4 to 83.9) | 91.8% (84.0 to 96.3) | 100% (81.8 to 100) | Â | Â | Â |
Second season | 50.5% (24.3 to 67.7) | 76.2% (63.0 to 85.0) | 92.2% (65.6 to 99.1) | Â | Â | Â |
Third-fifth season | Calculated | Calculated | Calculated | Â | Efficacy during third to fifth season calculated as linear decline equal to reduction between first and second season | Â |
RV5 | Â | Â | Â | Â | Â | Â |
After first dose | Calculated | Calculated | 88% (65 to 97) | Calculated | (Calculated from) Published data Efficacy after first dose and between first and second dose for mild and moderate cases calculated from efficacy ratios for mild, moderate, severe during first season | [57] |
After second dose | Calculated | Calculated | 88% (69 to 96) | Â | Â | Â |
First season (after third dose) | 65.1% (54.1 to 73.5) | 72.0% (63.2 to 78.9) | 94.8% (89.4 to 97.8) | Â | (Calculated from) Published data | |
Second season | 49.8% (27.0 to 65.4) | 58.5% (40.1 to 71.7) | 90.8% (76.9 to 97.1) | Â | Â | Â |
Third season | Calculated | Calculated | 100.0% (27.9 to 100) | Â | Efficacy during third season for mild and moderate cases calculated from efficacy ratios for mild, moderate, severe during second season | [55] |
Fourth-fifth season | Calculated | Calculated | Calculated | Â | Efficacy during third to fifth season calculated as linear decline equal to reduction between first and second season | Â |